Bedrijfsoverzicht
Lunai Bioworks Inc. is a pre-clinical stage biotechnology entity that develops and provides medicine, diagnostics, and biodefense products to markets in the United States and the Netherlands. The company operates through three distinct segments identified as RENB, BioSymetrics, and RENC, focusing on the development of a genetically modified allogeneic dendritic cell therapy. Lunai Bioworks Inc. operates within the Healthcare sector and specifically within the Biotechnology industry, a domain characterized by high capital expenditure requirements and long development cycles for therapeutic products. The company's market capitalization stands at $8.97M, supported by a workforce of 29 employees, indicating a very small-scale operation relative to established pharmaceutical firms. This limited market cap and the absence of reported annual revenue figures suggest that Lunai Bioworks Inc. is currently in an early-stage development phase where commercialization has not yet generated significant cash flows, positioning it as a high-risk, high-potential venture dependent on future product approvals and commercial success.
Financiële gezondheid
The company reports Net Income (TTM) of $-125,523,440 and EBITDA of $-12,458,986, while Revenue (TTM) is listed as N/A, indicating a lack of commercial sales to date. The substantial gap between the negligible revenue and the massive net loss reveals a cost structure dominated by research and development expenses typical for pre-clinical biotechnology companies. Free Cash Flow stands at $-8,343,209, which signifies that the company is burning through its available cash reserves to fund operations and R&D activities rather than generating liquidity. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that reflects the inability to generate gross profit due to zero sales and the absence of operational profitability. On the balance sheet, Lunai Bioworks Inc. holds Cash of $491,645 against Total Debt of $2.75M, while the Debt to Equity ratio is listed as N/A due to the company's negative equity position. The Current Ratio is 0.03, a critically low figure that indicates severe short-term liquidity constraints and an inability to meet current liabilities with current assets. Furthermore, the Return on Equity is -366.4% and the Return on Assets is -13.3%, metrics that highlight how management is currently destroying shareholder value and utilizing assets inefficiently given the lack of income generation.
Waarderingsbeoordeling
Valuation multiples for Lunai Bioworks Inc. are largely non-existent or negative due to the company's financial status, with the P/E Ratio (TTM) and Forward P/E both listed as N/A. The Price to Book ratio is recorded at -0.66, which indicates that the market is valuing the company at a negative multiple of its book value, a common occurrence for distressed or unprofitable biotechnology firms with negative shareholder equity. Since Revenue is N/A, the Price to Sales ratio is also N/A, and the EV/EBITDA stands at -0.90, suggesting that traditional valuation models based on earnings or sales are not applicable to this pre-revenue entity. Regarding trading ranges, the 52-Week High is $5.50 and the 52-Week Low is $0.15, meaning the stock trades within a highly volatile range defined by these extremes. The Beta is 0.49, which implies that the stock's price volatility is significantly lower than the broader market, a counter-intuitive characteristic for a small-cap biotech stock that usually exhibits higher beta values. These metrics collectively suggest that investors cannot rely on standard valuation frameworks but must assess the firm based on the potential success of its pipeline rather than current financial ratios.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet achieved commercial revenue to calculate year-over-year expansion rates. Consequently, there is no data to determine whether earnings are growing faster or slower than revenue, as both metrics are currently non-existent in the financial history of the firm. Lunai Bioworks Inc. does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that the company retains all its limited cash resources to fund its research and development efforts rather than distributing income to shareholders. The overall growth and income profile is defined by a total absence of current income generation and historical growth data, relying entirely on future potential rather than past performance.